Abstract
In recent years, there is a new optimism in schizophrenia therapeutics with the emergence of immunomodulation as a potential treatment approach. Current evidence points to various immunological abnormalities in schizophrenia, including cell-mediated processes, acute phase proteins, cytokines, and intracellular mediators. Trait- and state-related immune dysfunction appears to exist, and a strong case can therefore be made for immunomodulation therapies in the prevention, treatment, and/or moderating the course of schizophrenia.
Immunomodulation approaches include use of nonsteroidal anti-inflammatory agents to stop or moderate an over-activated inflammatory process, anti-oxidants, nutrients, vitamins, herbal products, and other neuroprotection agents that inhibit pro-inflammatory processes, optimal use of antipsychotic drugs (APDs) that may have anti-inflammatory actions or in certain cases such as clozapine may enhance blunted inflammatory responses, and biological agents to antagonize specific immune mediators such as the cytokines. A combination of two or more of the above approaches is also worthy of consideration.
In this chapter, the available data for each of the above approaches is reviewed and discussed. Strengths and limitations of current studies are identified, and suggestions are made for future studies. For example, identifying patients with high levels of specific biomarkers such as C-Reactive Protein, IL-6, IFN-γ, TNF-α, and genetic polymorphisms of cytokines, and match them with clinical subgroups such as prodromal, first episode psychosis, chronic psychosis, and negative symptoms with the aim of developing targeted treatment approaches and more personalized medicine. Meanwhile, since the science and trial data are not advanced enough to make definitive recommendations, clinicians should stay up to date with the literature, obtain detailed immunological histories, and review the risk-benefit ratio of adding available immune modulating agents to standard therapies, to provide optimal and state-of-the-art care to patients.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Arias I, Sorlozano A, Villegas E et al (2012) Infectious agents associated with schizophrenia: a meta-analysis. Schizophr Res 136:128–136
Arroll MA, Wilder L, Neil J (2014) Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review. Nutr J 13:91
Baumeister D, Ciufolini S, Mondelli V (2016) Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment? Psychopharmacology (Berl) 233(9):1575–1589
Bumb JM, Enning F, Leweke FM (2015) Drug repurposing and emerging adjunctive treatments for schizophrenia. Expert Opin Pharmacother 16(7):1049–1067
Chan MK, Guest PC, Levin Y et al (2011) Chapter 5 – Converging evidence of blood-based biomarkers for schizophrenia: an update. Int Rev Neurobiol 101:95–144
Chen ML, Tsai TC, Wang LK et al (2012) Risperidone modulates the cytokine and chemokine release of dendritic cells and induces TNF-α-directed cell apoptosis in neutrophils. Int Immunopharmacol 12(1):197–204
Cox D, Chan MK, Bahn S (2015) The potential of immune biomarkers to advance personalized medicine approaches for schizophrenia. J Nerv Ment Dis 203(5):393–399
de Witte L, Tomasik J, Schwarz E (2014) Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment. Schizophr Res 154(1–3):23–29
Deakin B, Suckling J, Barnes TRE et al (2018) The benefit of minocycline (Benemin) on negative symptoms of schizophrenia with recent onset psychosis. Lancet Psychiatry 5(11):885–894
Debnath M, Venkatasubramanian G (2013) Recent advances in psychoneuroimmunology relevant to schizophrenia therapeutics. Curr Opin Psychiatry 26(5):433–439
Diaz FJ, Pérez-Iglesias R, Mata I et al (2010) Possible effects of some antipsychotic drugs on C-reactive protein in a drug-naïve psychotic sample. Schizophr Res 121(1–3):207–212
Girgis RR, Kumar SS, Brown AS (2014) The cytokine model of schizophrenia: emerging therapeutic strategies. Biol Psychiatry 75(4):292–299
Girgis RR, Ciarleglio A, Choo T et al (2017) A randomized, double-blind, placebo-controlled clinical trial of tocilizumab, an interleukin-6 receptor antibody, for residual symptoms in schizophrenia. Neuropsychopharmacology 43(6):1317–1323
Hartwig FP, Borges MC, Horta BL, Bowden J et al (2017) Inflammatory biomarkers and risk of schizophrenia: a 2-sample Mendelian randomization study. JAMA Psychiat 74(12):1226–1233
Joy CB, Mumby-Croft R, Joy LA (2006) Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst Rev 19(3):CD001257
Kane JM, Correll CU (2010) Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry 71(9):1115–1124
Khandaker GM, Pearson RM, Zammit S et al (2014) Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiat 71(10):1121–1128
Khandaker GM, Zammit S, Burgess S et al (2018) Association between a functional interleukin 6 receptor genetic variant and risk of depression and psychosis in a population-based birth cohort. Brain Behav Immun 69:264–272
Maes M, Delange J, Ranjan R et al (1997) Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res 66:1–11
McGorry PD, Nelson B, Markulev C et al (2017) Effect of ω-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial. JAMA Psychiat 74(1):19–27. https://doi.org/10.1001/jamapsychiatry.2016.2902
Miller BJ, Buckley PF (2016) The case for adjunctive monoclonal antibody immunotherapy in schizophrenia. Psychiatr Clin N Am 39:187–198
Miller BJ, Buckley P, Seabolt W et al (2011) Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70:663–671
Müller N (2014) Immunology of schizophrenia. Neuroimmunomodulation 21:109–116
Müller N, Myint AM, Krause D et al (2013) Anti-inflammatory treatment in schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 42:146–153
Nitta M, Kishimoto T, Muller N et al (2013) Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr Bull 6:1230–1241
Potvin S, Stip E, Sepehry AA et al (2008) Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 63(8):801–808
Raison CL, Rutherford RE, Woolwine BJ et al (2013) A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiat 70(1):31–41
Rolland B, Deguil J, Jardri R et al (2013) Therapeutic prospects of PPARs in psychiatric disorders: a comprehensive review. Curr Drug Targets 14(7):724–732
Sommer IE, van Westrhenen R, Begemann MJ et al (2014) Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull 40(1):181–191
Torrey EF, Davis JM (2012) Adjunct treatments for schizophrenia and bipolar disorder: what to try when you are out of ideas. Clin Schizophr Relat Psychoses 5(4):208–216
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Pandurangi, A.K., Buckley, P.F. (2019). Inflammation, Antipsychotic Drugs, and Evidence for Effectiveness of Anti-inflammatory Agents in Schizophrenia. In: Khandaker, G., Meyer, U., Jones, P. (eds) Neuroinflammation and Schizophrenia. Current Topics in Behavioral Neurosciences, vol 44. Springer, Cham. https://doi.org/10.1007/7854_2019_91
Download citation
DOI: https://doi.org/10.1007/7854_2019_91
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-39140-9
Online ISBN: 978-3-030-39141-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)